Lotivibart Biosimilar Monoclonal Antibody (HIV-1 gp120) for Research

Cat No.: GMP-Bios-INN-1266

Anti-HIV-1 gp120 therapeutic antibody (Pre-made Lotivibart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Lotivibart (development codes N6LS/VH3810109) is a monoclonal antibody targeting HIV-1 gp120 envelope glycoprotein. It is developed for HIV-1 infection. Further development details are under investigation.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1266-1mg 1mg 3090
GMP-Bios-INN-1266-10mg 10mg
GMP-Bios-INN-1266-100mg 100mg
GMP-Bios-INN-1266-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Lotivibart biosimilar, Whole mAb: Anti-HIV-1 gp120 therapeutic antibody
INN Name Lotivibart
Target HIV-1 gp120
Format Whole mAb
Derivation Human
Species Reactivity Human
CH1+2+3 Isotype G1
VD LC Kappa
Highest_Clin_Trial (Jan '20) TBC
Est. Status Active
100% SI Structure None
99% SI Structure None
95-98% SI Structure 5te4:HL/5te5:HL/5th6:HL
Year Proposed 2024
Year Recommended na
Companies TBC
Conditions Approved TBC
Conditions Active TBC
Conditions Discontinued TBC
Production na
Development Tech TBC